Timi Flow Between Streptokinase and Alteplase in Successful Fibrinolytic
DOI:
https://doi.org/10.32734/sumej.v2i1.716Keywords:
STEMI, Fibrinolytic, Streptokinase, Alteplase, TIMI FlowAbstract
STEMI with onset≤12 hours, necessary to take Primary Percutaneous Coronary Intervention (pPCI), but if there is no facility, another therapy is fibrinolytic, to improve blood flow in the coronary artery and myocardial function, thus reducing infarction expansion.
This is a retrospective study in STEMI patients onset≤12 hours, had performed successful fibrinolytic with Streptokinase (SK) and Alteplase (tPA) from January 2015 to August 2017. TIMI flow was assessed by coronary angiography. There were 54 patients who had performed successful fibrinolytic therapy with SK and tPA; each group had 27 patients. In the SK group, there were nine patients (33.3%) with TIMI flow 2 and 18 patients (66.7%) with TIMI flow 3. While in the tPA group there were 11 patients (40.7%) with TIMI flow 2, 16 patients (59.3%) with TIMI flow 3, (p=0.573). There is no difference in TIMI flow between SK and tPA on STEMI patients after success fibrinolytic therapy.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
The Authors submitting a manuscript do so on the understanding that if accepted for publication, copyright of the article shall be assigned to Sumatera Medical Journal (SUMEJ) and Faculty of Medicine as well as TALENTA Publisher Universitas Sumatera Utara as publisher of the journal.
Copyright encompasses exclusive rights to reproduce and deliver the article in all form and media. The reproduction of any part of this journal, its storage in databases and its transmission by any form or media, will be allowed only with a written permission from Sumatera Medical Journal (SUMEJ).
The Copyright Transfer Form can be downloaded here.
The copyright form should be signed originally and sent to the Editorial Office in the form of original mail or scanned document.
